BIO-TECHNE Corp vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $46.99. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals.
| TECH | USOI | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $72.12 | $61.17 |
52-Week Low | $43.31 | $42.27 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
USOI, the Credit Suisse X-Links Crude Oil Shares Covered Call ETN, trades at $46.84, up 0.09% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The instrument's exceptionally high yield, cited as over 30% by 24/7 Wall Street on 2026-05-19, draws investor attention amid oil market volatility driven by geopolitical events like the Iran War, as reported on 2026-04-26. Key support sits at $45 with resistance at $47.
The outlook hinges on crude oil price movements and covered call strategy performance, offering high income potential but carrying significant risks from oil volatility and the ETN structure, which differs from traditional ETFs. Investors face concentration risk in energy markets and potential capital erosion if oil trends lower.
Trailing returns across standard periods
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →